CA2595902C - Composes liants, composes immunogenes et composes peptidomimetiques de la boucle en epingle a cheveux ss-3 des facteurs de croissance a noeud decystine - Google Patents

Composes liants, composes immunogenes et composes peptidomimetiques de la boucle en epingle a cheveux ss-3 des facteurs de croissance a noeud decystine Download PDF

Info

Publication number
CA2595902C
CA2595902C CA2595902A CA2595902A CA2595902C CA 2595902 C CA2595902 C CA 2595902C CA 2595902 A CA2595902 A CA 2595902A CA 2595902 A CA2595902 A CA 2595902A CA 2595902 C CA2595902 C CA 2595902C
Authority
CA
Canada
Prior art keywords
scaffold
cysv
cysiv
peptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2595902A
Other languages
English (en)
Other versions
CA2595902A1 (fr
Inventor
Peter Timmerman
Wouter Cornelis Puijk
Jelle Wouter Slootstra
Evert Van Dijk
Robbert Hans Meloen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pepscan Systems BV
Original Assignee
Pepscan Systems BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pepscan Systems BV filed Critical Pepscan Systems BV
Publication of CA2595902A1 publication Critical patent/CA2595902A1/fr
Application granted granted Critical
Publication of CA2595902C publication Critical patent/CA2595902C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
CA2595902A 2005-01-24 2006-01-24 Composes liants, composes immunogenes et composes peptidomimetiques de la boucle en epingle a cheveux ss-3 des facteurs de croissance a noeud decystine Expired - Fee Related CA2595902C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05075174 2005-01-24
EP05075174.2 2005-01-24
EP05077896 2005-12-16
EP05077896.2 2005-12-16
PCT/NL2006/000036 WO2006078161A1 (fr) 2005-01-24 2006-01-24 Composes liants, composes immunogenes et composes peptidomimetiques

Publications (2)

Publication Number Publication Date
CA2595902A1 CA2595902A1 (fr) 2006-07-27
CA2595902C true CA2595902C (fr) 2017-08-22

Family

ID=36168379

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2595902A Expired - Fee Related CA2595902C (fr) 2005-01-24 2006-01-24 Composes liants, composes immunogenes et composes peptidomimetiques de la boucle en epingle a cheveux ss-3 des facteurs de croissance a noeud decystine

Country Status (13)

Country Link
US (1) US7863239B2 (fr)
EP (1) EP1844337B1 (fr)
JP (1) JP5372380B2 (fr)
AU (1) AU2006206848B2 (fr)
CA (1) CA2595902C (fr)
CY (1) CY1114441T1 (fr)
DK (1) DK1844337T3 (fr)
ES (1) ES2428869T3 (fr)
NZ (1) NZ560504A (fr)
PL (1) PL1844337T3 (fr)
PT (1) PT1844337E (fr)
SI (1) SI1844337T1 (fr)
WO (1) WO2006078161A1 (fr)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099746A1 (fr) * 2004-04-13 2005-10-27 St Vincent's Hospital Sydney Limited Procede pour la modulation de l'appetit
US7598356B2 (en) 2004-07-08 2009-10-06 Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center Method for purifying a protein of the cystine-knot superfamily
DE102005022047A1 (de) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
WO2008013454A2 (fr) * 2006-07-26 2008-01-31 Pepscan Systems B.V. Composés immunogènes et mimiques moléculaires
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
JP5656407B2 (ja) 2006-12-14 2015-01-21 エイルロン セラピューティクス，インコーポレイテッド ビス−スルフヒドリル大環状化系
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
ES2648687T3 (es) 2007-02-23 2018-01-05 Aileron Therapeutics, Inc. Péptidos macrocíclicos unidos a triazol
EP2508531B1 (fr) 2007-03-28 2016-10-19 President and Fellows of Harvard College Polypeptides piqués
EP2257624B9 (fr) * 2008-02-05 2012-08-01 Medical Research Council Procédés et compositions
JPWO2009107771A1 (ja) * 2008-02-27 2011-08-04 国立大学法人大阪大学 金−酸化鉄複合ナノ粒子を用いたペプチドの合成方法
AU2010204648B2 (en) 2009-01-14 2016-09-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
GB0914110D0 (en) * 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
CA2774973A1 (fr) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
PT2603600T (pt) 2010-08-13 2019-02-27 Aileron Therapeutics Inc Macrociclos peptidomiméticos
GB201013980D0 (en) 2010-08-20 2010-10-06 Ecole Polytech Bicyclic uPA inhibitors
WO2012075340A2 (fr) 2010-12-01 2012-06-07 Alderbio Holdings Llc Compositions anti-ngf et leur utilisation
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
EP2651964B1 (fr) 2010-12-15 2018-02-28 The Research Foundation of State University of New York Peptides et protéines réticulés, leurs procédés de fabrication et leurs utilisations
CN107988156B (zh) 2011-06-30 2022-01-04 建新公司 T细胞活化的抑制剂
US20130101664A1 (en) 2011-08-18 2013-04-25 Donald W. Kufe Muc1 ligand traps for use in treating cancers
EP3299377B1 (fr) 2011-10-07 2020-12-09 BicycleRD Limited Modulation de la spécificité de polypeptide structurée
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
CA2852468A1 (fr) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques
EP2794636A1 (fr) * 2011-12-19 2014-10-29 Janssen R&D Ireland Inhibiteurs de fusion membranaire du vih
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
CA2864120A1 (fr) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques reticules par triazole et par thioether
RU2017145921A (ru) 2012-02-15 2019-02-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
CA2862516C (fr) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions et methodes d'utilisation pour le traitement de troubles metaboliques
EP2850095B1 (fr) 2012-05-17 2019-10-09 RA Pharmaceuticals, Inc. Inhibiteurs peptidiques et peptidomimétiques
US9556229B2 (en) 2012-05-18 2017-01-31 The Regents Of The University Of California Modification of peptides using a bis(thioether)arylbridge approach
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2014116789A1 (fr) * 2013-01-25 2014-07-31 Thymon, Llc Compositions immunogènes et prophylactiques, leurs procédés de fabrication, et méthode de traitement et de prévention d'une maladie médiée par le tnf et d'une infection par le vih-1
KR101759687B1 (ko) 2013-01-25 2017-07-19 타이몬, 엘엘씨 순환하는 생물활성 가용성 tnf의 선택적 감소를 위한 조성물 및 tnf-매개 질환의 치료 방법
WO2014120619A2 (fr) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions et procédés à utiliser pour le traitement de troubles métaboliques
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
EP2767549A1 (fr) 2013-02-19 2014-08-20 Adienne S.A. Anticorps anti-CD26 et leurs utilisations
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
WO2014207534A2 (fr) * 2013-06-25 2014-12-31 Sépia Pesquisa E Desenvolvimento Modulateurs des récepteurs de la bradykinine et leur utilisation
CN105683211B (zh) 2013-10-28 2020-10-20 拜斯科阿迪有限公司 新型多肽
US10822604B2 (en) 2014-05-02 2020-11-03 Morphosys Ag Peptide libraries
BR112016029076B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Polipeptídeo e composição compreendendo o mesmo para inibir a clivagem de c5 em um sistema celular
EP3174894B1 (fr) 2014-07-30 2021-06-23 NGM Biopharmaceuticals, Inc. Compositions et méthodes d'utilisation pour le traitement de troubles métaboliques
CN112972378A (zh) 2014-09-24 2021-06-18 艾瑞朗医疗公司 拟肽大环化合物及其制剂
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US10532106B2 (en) 2014-10-29 2020-01-14 Bicyclerd Limited Bicyclic peptide ligands specific for MT1-MMP
NZ730054A (en) 2014-10-31 2023-11-24 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
SI3250230T1 (sl) 2015-01-28 2022-01-31 Ra Pharmaceuticals, Inc. Modulatorji aktivnosti komplementa
BR112017019738A2 (pt) 2015-03-20 2018-05-29 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP7056932B2 (ja) 2015-08-25 2022-04-19 ヒスタイド アクツィエンゲゼルシャフト 組織形成誘導用化合物及びその使用
WO2017044633A1 (fr) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques en tant que modulateurs de mcl-1
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
HUE053697T2 (hu) * 2015-09-17 2021-07-28 Histide Ag Neoplasztikus sejt nem neoplasztikus sejtté alakításához használt gyógyszerészeti együttes, mely egy növekedésifaktor-receptor agonistából és egy adhéziós fehérjeinhibitorból áll, és ezek felhasználása
WO2017046229A1 (fr) * 2015-09-17 2017-03-23 Histide Ag Association pharmaceutique d'un agoniste d'un récepteur des facteurs de croissance et d'un inhibiteur de protéines d'adhésion pour convertir des cellules néoplasiques en cellules non-néoplasiques, et utilisation de cette dernière
WO2017046228A2 (fr) * 2015-09-17 2017-03-23 Histide Ag Association pharmaceutique pour convertir une cellule néoplasique en cellule non-néoplasique, et ses utilisations
AU2016370210A1 (en) 2015-12-16 2018-06-21 Ra Pharmaceuticals, Inc. Modulators of complement activity
GB201600911D0 (en) 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives
GB201600903D0 (en) 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Peptide derivaties
CN109715206B (zh) 2016-03-31 2023-11-07 恩格姆生物制药公司 结合蛋白及其使用方法
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
EP3544621A1 (fr) 2016-11-27 2019-10-02 BicycleRD Limited Méthodes pour le traitement du cancer
CN110087668A (zh) 2016-12-07 2019-08-02 Ra制药公司 补体活性的调节剂
CN110506049A (zh) 2016-12-23 2019-11-26 拜斯科技术开发有限公司 用于结合mt1-mmp的肽配体
EP3559018A1 (fr) 2016-12-23 2019-10-30 Bicyclerd Limited Dérivés peptidiques ayant de nouvelles structures de liaison
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
CN111183147A (zh) 2017-08-04 2020-05-19 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
EP3668887A1 (fr) 2017-08-14 2020-06-24 Bicyclerd Limited Conjugués ligands peptidiques bicycliques et leurs utilisations
EP3668550A1 (fr) 2017-08-14 2020-06-24 Bicyclerd Limited Conjugués peptide bicyclique-ligand ppr-a et leurs utilisations
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
MX2020008791A (es) 2018-02-23 2021-01-08 Bicycletx Ltd Ligandos de peptidos biciclicos multimericos.
SG11202009773VA (en) 2018-04-04 2020-10-29 Bicycletx Ltd Heterotandem bicyclic peptide complexes
GB201808835D0 (en) 2018-05-30 2018-07-11 Bicyclerd Ltd Ligands and methods of selecting binding targets for such
GB201810327D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810329D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
GB201810320D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
EP3870597A1 (fr) 2018-10-23 2021-09-01 BicycleTx Limited Ligands peptidiques bicycliques et leurs utilisations
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820320D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
AU2019398516A1 (en) 2018-12-13 2021-08-05 Bicycletx Limited Bicyclic peptide ligands specific for MT1-MMP
EP3897850A1 (fr) 2018-12-21 2021-10-27 Bicyclerd Limited Ligands peptidiques bicycliques spécifiques à pd-l1
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
WO2020165600A1 (fr) 2019-02-14 2020-08-20 Bicycletx Limited Conjugués peptide-ligand bicyclique et leurs utilisations
WO2020178574A1 (fr) 2019-03-04 2020-09-10 Bicyclerd Limited Synthèse de conjugués de toxines bicycliques et leurs intermédiaires
TW202110485A (zh) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4013501A1 (fr) 2019-08-13 2022-06-22 BicycleTX Limited Ligands peptidiques bicycliques multimères modifiés
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
GB201914233D0 (en) 2019-10-02 2019-11-13 Bicyclerd Ltd Phage cyclisation assay
CN114867753A (zh) 2019-10-03 2022-08-05 拜斯科技术开发有限公司 异串联双环肽复合物
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
GB201918557D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918558D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
CN114787177A (zh) 2019-12-16 2022-07-22 拜斯科技术开发有限公司 Il-17特异性的双环肽配体
GB201918559D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
JP2023520714A (ja) 2020-04-06 2023-05-18 バイスクルテクス・リミテッド Ｔｓｌｐに特異的な二環式ペプチドリガンド
WO2021220011A1 (fr) 2020-05-01 2021-11-04 Bicycletx Limited Conjugués peptidiques bicycliques anti-infectieux
CN116018349A (zh) 2020-05-15 2023-04-25 拜斯科技术开发有限公司 抗感染的双环肽配体
GB202016331D0 (en) 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
MX2023008168A (es) 2021-01-08 2023-07-25 Bicycletx Ltd Complejos peptidicos biciclicos heterotandem.
US20240108737A1 (en) 2021-01-08 2024-04-04 Bicycletx Limited Anti-infective bicyclic peptide ligands
EP4274837A1 (fr) 2021-01-08 2023-11-15 BicycleTx Limited Ligands peptidiques bicycliques anti-infectieux
JP2024504077A (ja) 2021-01-08 2024-01-30 バイスクルテクス・リミテッド 抗感染性二環式ペプチドリガンド
EP4274843A1 (fr) 2021-01-08 2023-11-15 BicycleTx Limited Ligands peptidiques bicycliques anti-infectieux
EP4274839A1 (fr) 2021-01-08 2023-11-15 BicycleTx Limited Ligands peptidiques bicycliques anti-infectieux
WO2022148979A1 (fr) 2021-01-11 2022-07-14 Bicycletx Limited Méthodes de traitement du cancer
WO2023031623A2 (fr) 2021-09-03 2023-03-09 Bicycletx Limited Synthèse de conjugués de toxines bicycliques et leurs intermédiaires
GB202114279D0 (en) 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
GB202114282D0 (en) 2021-10-06 2021-11-17 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
GB202116266D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Novel use
WO2023139292A1 (fr) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Thérapie anti-tau
WO2024009108A1 (fr) 2022-07-07 2024-01-11 Bicycletx Limited Ligands peptidiques bicycliques anti-infectieux

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047042A1 (fr) 1990-07-19 1992-01-20 John Hannah Peptides cycliques neutralisant le vih
US7994278B1 (en) * 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
FR2839452A1 (fr) 2002-05-07 2003-11-14 Pf Medicament Utilisation de peptide derive de la sous-unite beta de l'hcg pour generer une reponse de type ctl antitumorale
GB0213878D0 (en) 2002-06-17 2002-07-31 Protherics Plc Use
EP1452868A2 (fr) 2003-02-27 2004-09-01 Pepscan Systems B.V. Procédé pour sélectionner un médicament d'intérêt potentiel

Also Published As

Publication number Publication date
DK1844337T3 (da) 2013-09-30
US7863239B2 (en) 2011-01-04
CA2595902A1 (fr) 2006-07-27
PT1844337E (pt) 2014-04-03
ES2428869T3 (es) 2013-11-12
JP2008529482A (ja) 2008-08-07
NZ560504A (en) 2009-07-31
AU2006206848A1 (en) 2006-07-27
JP5372380B2 (ja) 2013-12-18
PL1844337T3 (pl) 2013-12-31
SI1844337T1 (sl) 2013-11-29
WO2006078161A1 (fr) 2006-07-27
US20080313749A1 (en) 2008-12-18
EP1844337B1 (fr) 2013-07-03
CY1114441T1 (el) 2016-08-31
EP1844337A1 (fr) 2007-10-17
AU2006206848B2 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
CA2595902C (fr) Composes liants, composes immunogenes et composes peptidomimetiques de la boucle en epingle a cheveux ss-3 des facteurs de croissance a noeud decystine
AU2007277556B2 (en) Immunogenic compounds and protein mimics
US9176127B2 (en) Method for selecting a candidate drug compound
Trier et al. Production and characterization of peptide antibodies
JP4808756B2 (ja) タンパク質結合部位の同定
Wang et al. Blocking peptides against HBV: preS1 protein selected from a phage display library
CN107446040B (zh) 人st2抗原表位肽、抗原、抗体、试剂盒及应用
RU2356576C1 (ru) СИНТЕТИЧЕСКИЙ АНТИГЕН, ОБЛАДАЮЩИЙ СПОСОБНОСТЬЮ СВЯЗЫВАТЬ АУТОАНТИТЕЛА К β1-АДРЕНОРЕЦЕПТОРУ
US20120178682A1 (en) GB1 Peptidic Compounds and Methods for Making and Using the Same
RU2452964C1 (ru) СПОСОБ ИММУНОФЕРМЕНТНОГО АНАЛИЗА ДЛЯ ОПРЕДЕЛЕНИЯ АУТОАНТИТЕЛ К β1-АДРЕНОРЕЦЕПТОРУ В ПЛАЗМЕ И СЫВОРОТКЕ КРОВИ ЧЕЛОВЕКА
Spetzler et al. Synthetic hFSH peptide constructs in the evaluation of previous studies on the hFSH receptor interaction
CN107266552A (zh) 源自于prame的肿瘤抗原短肽

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190124